(NASDAQ: UNCY) Unicycive Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Unicycive Therapeutics's revenue in 2025 is $0.On average, 3 Wall Street analysts forecast UNCY's revenue for 2025 to be $1,772,831,435, with the lowest UNCY revenue forecast at $34,714,458, and the highest UNCY revenue forecast at $4,788,201,040. On average, 3 Wall Street analysts forecast UNCY's revenue for 2026 to be $50,756,487,189, with the lowest UNCY revenue forecast at $20,875,359,484, and the highest UNCY revenue forecast at $71,823,015,600.
In 2027, UNCY is forecast to generate $101,896,868,397 in revenue, with the lowest revenue forecast at $48,528,417,540 and the highest revenue forecast at $136,272,201,598.